Cyclophosphamid Sandoz (Cyclophosphamide)

Cyclophosphamid Sandoz is indicated for a range of malignant and immune‑mediated disorders in which cytotoxic therapy is required, typically as part of combination regimens administered by a specialist.

• Non‑Hodgkin lymphoma, including aggressive subtypes.
• Chronic lymphocytic leukemia.
• Breast cancer, often in adjuvant or metastatic settings.
• Ovarian and testicular cancers.
• Multiple myeloma and selected autoimmune diseases such as systemic lupus erythematosus.
• Other solid tumors where alkylating agents are part of standard protocols.

Side effects of Cyclophosphamid Sandoz reflect its alkylating mechanism and can involve multiple organ systems; they are categorized as common or serious based on frequency and clinical impact.

Common

• Nausea, vomiting, and loss of appetite.
• Transient decrease in white blood cells (leukopenia or neutropenia).
• Irritative cystitis with urinary urgency or mild hematuria.
• Mild alopecia (hair thinning or loss).

Serious

• Severe bone marrow suppression with infection risk.
• Hemorrhagic cystitis causing gross hematuria.
• Cardiotoxicity or secondary leukemia at high cumulative doses.
• Hepatotoxicity with elevated liver enzymes.

Before initiating Cyclophosphamid Sandoz, clinicians should evaluate patient-specific factors and monitor for potential toxicities, as the drug carries several important precautions.

• Assess baseline blood counts and liver function tests.
• Screen for pre‑existing bladder disease; ensure adequate hydration.
• Evaluate cardiac function in patients with prior heart disease.
• Use pregnancy testing; avoid use in pregnant women due to unknown risk.
• Adjust dose in renal impairment or elderly patients.
• Monitor for signs of infection or bleeding during therapy.

Cyclophosphamid Sandoz can interact with other medications that affect its metabolism or increase toxicity; awareness of these interactions helps optimize safety.

Avoid

• Concomitant use with strong CYP2B6 inducers (e.g., rifampin) that may reduce efficacy.
• Co‑administration with other alkylating agents that heighten bone‑marrow suppression.

Use with caution

• Concurrent use of nephrotoxic drugs (e.g., cisplatin) may worsen renal effects.
• Anticoagulants, as cyclophosphamide can increase bleeding risk.
• Live vaccines, because immunosuppression may reduce vaccine efficacy.
• Azathioprine or other immunosuppressants, requiring close monitoring.